Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment

Arcellx Inc. (NASDAQ:ACLX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, the company delivered promising Pivotal Phase 2 study results of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma. The company is developing an anti-CD in partnership with Kite, a Gilead company unit, ahead of the planned 2026 commercial launch. Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment Sergey Nivens/Shutterstock.com T ...